Search Results for keywords:"NIAID"

The National Institute of Allergy and Infectious Diseases (NIAID) announced two upcoming closed meetings as required by law. These meetings, scheduled for January 28-29, 2021, will focus on reviewing and evaluating contract proposals related to Small Business Innovation Research. The discussions are closed to the public to protect confidential information and personal privacy. Interested parties can contact Soheyla Saadi, Ph.D., for more information.

The National Institute of Allergy and Infectious Diseases (NIAID) is holding a closed meeting on April 24, 2025, to review grant applications related to inducing HIV immunity in early life. This meeting will take place at the NIAID's facility in Rockville, Maryland, and will be conducted via video assistance. The discussions will cover confidential trade secrets and personal information, which is why the meeting is not open to the public. The meeting is organized under the guidelines of the Federal Advisory Committee Act.

The National Institute of Allergy and Infectious Diseases (NIAID) is holding a closed meeting to review and evaluate contract proposals. This meeting will involve discussions about confidential trade secrets and personal information, which is why it’s not open to the public. The meeting is scheduled for April 3-4, 2025, from 9:00 a.m. to 6:00 p.m., and will be conducted via video assistance at the NIAID location in Rockville, Maryland. The meeting addresses a solicitation focused on vaccine adjuvant development as part of the Small Business Innovation Research (SBIR) program.

The National Institute of Allergy and Infectious Diseases (NIAID) is holding a closed meeting from April 24-29, 2025, to review grant applications. This meeting will be conducted virtually and is closed to the public to protect confidential information, including trade secrets and personal privacy. The meeting is part of a special emphasis panel for the NIAID New Innovators Awards. The contact person for the meeting is Frank S. De Silva, Ph.D., who works with the Scientific Review Program at the National Institutes of Health.

The National Institute of Allergy and Infectious Diseases (NIAID) announced a closed meeting for the Special Emphasis Panel focused on promoting research in Treponema Pallidum pathogenesis. This meeting, scheduled for April 8, 2025, will take place from 10:00 a.m. to 6:00 p.m. via a video-assisted format. The review and evaluation of grant applications will occur, and sensitive information will remain confidential due to privacy and trade secret concerns. Queries can be directed to Dr. Mairi Noverr, the designated contact at NIAID.

The National Institute of Allergy and Infectious Diseases (NIAID) scheduled a meeting for March 23, 2021, to review and evaluate contract proposals. This meeting is closed to the public to protect confidential information and personal privacy, in line with federal regulations. The committee involved is the Special Emphasis Panel for the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC), and the session will be held virtually. For more information, contact Margaret A. Morris Fears, Ph.D., at the NIAID.

The National Institute of Allergy and Infectious Diseases (NIAID) will hold a closed meeting on May 8, 2025, from 2:00 p.m. to 5:00 p.m. This meeting, conducted via video assistance, will focus on reviewing and evaluating grant applications for the NIAID Investigator Initiated Program Project Applications. The meeting will not be open to the public to protect confidential information, including trade secrets and personal details. Lindsey M. Pujanandez, Ph.D., will serve as the Scientific Review Officer for the meeting.

The National Institute of Allergy and Infectious Diseases (NIAID) is offering royalty-free access to a specially developed starting material, known as "MVA clone-1," for creating and commercializing a vaccine against mpox. This initiative aims to improve vaccine access, especially in underserved regions, and respond to a 2024 public health emergency called by the World Health Organization due to a significant outbreak in the Democratic Republic of the Congo. Interested parties with solid plans to develop and distribute the vaccine in high-need areas can collaborate with NIAID. The material shows promise as it is similar to an already approved vaccine and has been shown to protect against mpox in both normal and at-risk populations.